Exact Sciences Stock Revenue
| EXAS Stock | USD 56.11 4.26 7.06% |
EXACT Sciences fundamentals help investors to digest information that contributes to EXACT Sciences' financial success or failures. It also enables traders to predict the movement of EXACT Stock. The fundamental analysis module provides a way to measure EXACT Sciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to EXACT Sciences stock.
EXACT |
EXACT Sciences Company Revenue Analysis
EXACT Sciences' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current EXACT Sciences Revenue | 2.5 B |
Most of EXACT Sciences' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, EXACT Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of EXACT
Projected quarterly revenue analysis of EXACT Sciences provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of EXACT Sciences match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in EXACT Sciences' stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, EXACT Sciences reported 2.5 B of revenue. This is 67.22% lower than that of the Biotechnology sector and 26.15% higher than that of the Health Care industry. The revenue for all United States stocks is 73.5% higher than that of the company.
EXACT Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses EXACT Sciences' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of EXACT Sciences could also be used in its relative valuation, which is a method of valuing EXACT Sciences by comparing valuation metrics of similar companies.EXACT Sciences is currently under evaluation in revenue category among its peers.
EXACT Sciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, EXACT Sciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to EXACT Sciences' managers, analysts, and investors.Environmental | Governance | Social |
EXACT Sciences Institutional Holders
Institutional Holdings refers to the ownership stake in EXACT Sciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of EXACT Sciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing EXACT Sciences' value.| Shares | T. Rowe Price Associates, Inc. | 2024-09-30 | 3.3 M | Geode Capital Management, Llc | 2024-09-30 | 3.1 M | Champlain Investment Partners, Llc | 2024-09-30 | 2.5 M | Holocene Advisors, Lp | 2024-09-30 | 1.9 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1.8 M | Macquarie Group Ltd | 2024-09-30 | 1.5 M | Cam Group Holding A/s | 2024-09-30 | 1.5 M | Bellevue Group Ag | 2024-09-30 | 1.4 M | Zevenbergen Capital Investments Llc | 2024-09-30 | 1.4 M | Fmr Inc | 2024-09-30 | 21.6 M | Vanguard Group Inc | 2024-09-30 | 17.8 M |
EXACT Fundamentals
| Return On Equity | -0.0676 | ||||
| Return On Asset | -0.0216 | ||||
| Profit Margin | (0.08) % | ||||
| Operating Margin | (0.03) % | ||||
| Current Valuation | 12.91 B | ||||
| Shares Outstanding | 185.08 M | ||||
| Shares Owned By Insiders | 1.01 % | ||||
| Shares Owned By Institutions | 98.99 % | ||||
| Number Of Shares Shorted | 11.83 M | ||||
| Price To Earning | (38.17) X | ||||
| Price To Book | 3.48 X | ||||
| Price To Sales | 3.94 X | ||||
| Revenue | 2.5 B | ||||
| Gross Profit | 1.51 B | ||||
| EBITDA | 41.88 M | ||||
| Net Income | (204.15 M) | ||||
| Cash And Equivalents | 728.04 M | ||||
| Cash Per Share | 4.11 X | ||||
| Total Debt | 2.55 B | ||||
| Debt To Equity | 0.77 % | ||||
| Current Ratio | 2.48 X | ||||
| Book Value Per Share | 17.35 X | ||||
| Cash Flow From Operations | 156.12 M | ||||
| Short Ratio | 3.25 X | ||||
| Earnings Per Share | (1.16) X | ||||
| Price To Earnings To Growth | (1.07) X | ||||
| Target Price | 71.86 | ||||
| Number Of Employees | 6.5 K | ||||
| Beta | 1.27 | ||||
| Market Capitalization | 10.62 B | ||||
| Total Asset | 6.47 B | ||||
| Retained Earnings | (3.47 B) | ||||
| Working Capital | 679.67 M | ||||
| Current Asset | 325.86 M | ||||
| Current Liabilities | 26.72 M | ||||
| Net Asset | 6.47 B |
About EXACT Sciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze EXACT Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of EXACT Sciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of EXACT Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for EXACT Stock Analysis
When running EXACT Sciences' price analysis, check to measure EXACT Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EXACT Sciences is operating at the current time. Most of EXACT Sciences' value examination focuses on studying past and present price action to predict the probability of EXACT Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EXACT Sciences' price. Additionally, you may evaluate how the addition of EXACT Sciences to your portfolios can decrease your overall portfolio volatility.